Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Actinium Pharmaceuticals, Inc. (ATNM)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
4.9700-0.0600 (-1.19%)
At close: 04:00PM EDT
5.1800 +0.21 (+4.23%)
After hours: 07:28PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close5.0300
Open5.0500
Bid4.8000 x 800
Ask4.9800 x 800
Day's Range4.8900 - 5.0500
52 Week Range4.4100 - 10.3000
Volume121,708
Avg. Volume919,393
Market Cap118.209M
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)-1.1430
Earnings DateJun 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATNM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Actinium Pharmaceuticals, Inc.
    Technical Assessment: Bearish in the Intermediate-TermMonday provided a much-needed rest for the stock market after a very large rebound last week. Following that strong week (and we've seen this before during the current decline), the "bottom-callers" are out, but not in big numbers. That's probably a good thing, as others are calling this another bear-market rally. From a technical perspective and using our own interpretation, it is far too early to call the bottom as there is just not enough of the needed evidence.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
Advertisement
Advertisement